Harlan Waksal - 18 Mar 2024 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Executive Chair, Director
Signature
/s/ Jason Cavalier, Attorney-in-Fact for Harlan Waksal, M.D.
Issuer symbol
LYRA
Transactions as of
18 Mar 2024
Net transactions value
$0
Form type
4
Filing time
20 Mar 2024, 19:21:52 UTC
Previous filing
13 Nov 2023
Next filing
11 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYRA Common Stock Award $0 +275,000 +105% $0.000000 536,966 18 Mar 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on January 31, 2025.